Vertex Pharmaceuticals Incorporated

Nasdaq VERX · King Of Prussia, PA

Works in Genetic & rare · GI & liver · Hematology · Immunology · Infectious disease · Metabolic & endocrine · Neurology · Oncology · Renal & urogenital · Respiratory · Women's health

Vertex Pharmaceuticals Incorporated is a clinical trial sponsor based in King Of Prussia, PA, listed as Nasdaq VERX. It has 32 active clinical trials with 6,994 planned participants, across 11 therapeutic areas. Since 2021 it has completed 101 trials and stopped 4 early. Its FDA record on file shows 1 inspection.

Trial track record · since 2021

32Active trials6,994 planned participants
101Completed50 with results posted
4Stopped early4% of finished trials

FDA record

1InspectionLatest 2026-07-31: No action indicated
0Warning lettersNone on file
0RecallsNone on file

Recent FDA actions

Financials · Nasdaq VERX

Cash and equivalents
R&D expense
Net income (loss)
Cash runway

Pipeline · 32 active trials

StageTrialStatus

On the market

9 approved drug applications with a product on the market.

Questions about Vertex Pharmaceuticals Incorporated

See the rest of this profile

A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.

Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-10-30.

The FDA record counts inspection classifications, warning letters and recalls FDA has published that name this company. Compare it with the industry in the free CDMO FDA inspection lookup.

Approve Suite is not affiliated with Vertex Pharmaceuticals Incorporated.

See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.